Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
about
Pharmacological interventions for self-harm in adultsRamelteon for insomniaA review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdoseEffects of the Financial Crisis on Psychotropic Drug Consumption in a Cohort from a Semi-Urban Region in Catalonia, SpainMental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort studyAntipsychotic-related fatal poisoning, England and Wales, 1993-2013: impact of the withdrawal of thioridazine.Claims for sickness and disability benefits owing to mental disorders in the UK: trends from 1995 to 2014Trends in GP prescribing of psychotropic medications among young patients aged 16-24 years: a case study analysis.The psychoactive effects of psychiatric medication: the elephant in the room.Antidepressant use and lifetime history of mental disorders in a community sample: results from the Baltimore Epidemiologic Catchment Area Study.Antipsychotics, mood stabilisers, and risk of violent crimeUse of benzodiazepines and related drugs in Manitoba: a population-based studyRisk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation.Off-label drug use in Psychiatry Outpatient Department: A prospective study at a Tertiary Care Teaching HospitalLinking the evidence between urinary retention and antipsychotic or antidepressant drugs: A systematic review.Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms.Understanding the non-pharmacological correlates of self-reported efficacy of antidepressants.An end to depression in primary care?Quetiapine use in adults in the community: a population-based study in Alberta, Canada.Prescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study.Improving Access to Psychological Therapies and antidepressant prescribing rates in England: a longitudinal time-series analysis.Off-licence prescribing and regulation in psychiatry: current challenges require a new model of governance.Effects of depression and antidepressant medications on hip fracture: A population-based cohort study in Taiwan.Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study.Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries.Influences on antidepressant prescribing trends in the UK: 1995-2011.Effects of selective serotonin reuptake inhibitors on glaucoma: A nationwide population-based study.The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity.A retrospective study of psychotropic drug use among individuals with mental illness issued a community treatment order.Pharmacogenetics of second-generation antipsychotics.The reappraisal of benzodiazepines in the treatment of anxiety and related disorders.Prevalence, incidence, indication, and choice of antidepressants in patients with and without chronic kidney disease: a matched cohort study in UK Clinical Practice Research Datalink.Utilization of psychotropic drugs prescribed to persons with and without HIV infection: a Danish nationwide population-based cohort study.Prevalence and patterns of antidepressant switching amongst primary care patients in the UK.Modelling the cost-effectiveness of pharmacotherapy compared with cognitive-behavioural therapy and combination therapy for the treatment of moderate to severe depression in the UK.Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure.Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults.Pattern of psychotropic medication use over two decades in Australian women.The Isoxazole Ring and Its N-Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics.
P2860
Q24186543-76F202B1-C274-4E3D-86FF-2E9F4271DAF7Q24198232-46AB9AFE-3AB7-43D3-AB21-9D3327510458Q24606269-04DDF11A-193B-42C9-ACF6-2BD45970F6CAQ28550181-2F6C1830-50EE-404E-BC3E-4619FF8873DEQ28608168-91FCD2D1-458B-49A6-AFA1-3412978B48C4Q30251696-BE3BD379-B974-4A55-A458-D133955CBBA1Q30490038-572CE687-3529-437D-B328-30977A06316DQ33771325-EFC83D82-E1CE-41F1-BF14-5318E5155542Q33989385-8D4B185A-B005-4F87-AB3A-618F8AD4B927Q34041913-E645F34F-F0BC-4399-BAD7-EBE22817F740Q34194840-CDCCA6E6-5CCA-4980-A0E2-2A0B92AFD1AFQ34609374-EBD244EE-2019-43A3-B67E-02FFFE05DC37Q34659165-55079A06-A8BA-406A-96DB-40A1C7273B9AQ34708396-8462EE1B-F9EC-4AF1-9DDE-2364A2CD5A26Q35169598-D6A7F7A6-5BC5-445E-BF28-2D1BFA22C758Q35750383-D84166E0-8F71-41F2-91D2-E2B2923C353BQ35809210-FEAD0FB4-F9C0-479B-B6B4-80253E241AE3Q36143967-F0506B75-D1AB-42FD-9695-0179FBC48A4EQ36185825-D84B6B22-81F4-442C-8BD9-72F69BD81C10Q36732874-894B4C9F-911E-4BB4-AA74-D4DD19DFB123Q36983429-BBF22F34-F457-4697-8FCF-0D9CC0AA9617Q37114154-FEB23C6C-EC3F-43EC-8406-B9F9552502F6Q37248061-C6CDD8EE-9E87-4215-A4F1-FAF6A586A2D1Q37256907-D51C5100-BC35-41E4-817C-B1EDCF73E8D2Q37546344-9BD456A4-CA5B-4F44-85BD-1C5E756E123BQ37609140-DFD07EE8-AA45-4BC1-B7A2-31AF35AFEAB4Q37670602-C7F32D04-49C0-4144-A07C-6F59B37C394EQ37679735-3FDA75F0-4C8B-45D4-8EF9-9210C73D44E9Q38170310-84448571-6EF4-43BB-B0F9-8180A8A2B3ECQ38174188-60ED506C-9A32-4DF9-B396-EF8003498D11Q38217628-DC532F62-792D-4B13-B9C9-02B158672D99Q38252986-303C8A54-685D-459C-B347-54A07B0FCC0DQ38401618-749DDB0E-DFF9-4E31-BDB7-08436A205823Q38421984-915753AC-F4A0-4106-A0BE-278938EE7DFFQ38431558-AFAB3496-128B-4826-A834-4F51EB0235EEQ38514857-0BE94785-C649-4E1D-95A5-7F437C1E4D5BQ38652321-FFD73EB7-8ECB-4C7B-893A-2417B699F17DQ38739261-6B6F4F0E-9779-4A3D-B49C-E9B1F0BC0F2AQ38800074-C3FDDB8D-8FBB-42CF-A448-C5356CD8A7A8Q39157903-D48034BD-1A0B-4A6A-AAAB-29B4386A5BA2
P2860
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@ast
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@en
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@nl
type
label
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@ast
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@en
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@nl
prefLabel
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@ast
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@en
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@nl
P1476
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
@en
P2093
Joanna Moncrieff
Stephen Ilyas
P304
P356
10.1192/BJP.BP.111.104257
P407
P577
2012-03-22T00:00:00Z